BTX-1188 (HPK1 inhibitor)
Advanced Solid Tumors
Key Facts
About Ryvu Therapeutics
Ryvu Therapeutics is a Polish clinical-stage biotech focused on discovering and developing targeted small molecule therapies for cancer. Its strategy centers on tackling difficult-to-drug targets through a proprietary, integrated R&D platform, yielding a pipeline with both wholly-owned and partnered assets. Key achievements include advancing its lead program RVU120 into Phase I/II trials for hematological malignancies and securing a strategic partnership with BioNTech for its HPK1 inhibitor. The company aims to become a leader in precision oncology by translating novel biological insights into differentiated therapeutics.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |